U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Tinted Brew, Inc - 553052 - 07/31/2018
  1. Warning Letters

CLOSEOUT LETTER

Tinted Brew, Inc MARCS-CMS 553052 —

Recipient:
Tinted Brew, Inc

United States

Issuing Office:

United States

   

Department of Health and Human Services logo

  
 
Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring, MD 20993 

 

July 31, 2018
 
VIA UPS and Electronic Mail
 
Jonathan Nemr
Tinted Brew, Inc.
21416 Chase St.,Ste 1
Canoga Park, CA 91304-2547
info@tintedbrew.com
jon@tintedbrew.com
 
RE: Warning Letter issued to Tinted Brew Inc.(RW1800856)
 
Dear Jonathan Nemr:
 
On May 1, 2018, the United States Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your V’Nilla Cookies & Milk e-liquid product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. Specifically, FDA determined that the labeling and/or advertising of your V’Nilla Cookies & Milk e-liquid is misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children.
 
On May 22, 2018, June 7, 2018, July 2, 2018, and July 10, 2018, you sent FDA a response to the Warning Letter, and we held a teleconference on June 7, 2018 to discuss the Warning Letter and your response. In response to the Warning Letter, you stated that you implemented corrective actions to address the violation identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violation identified in the Warning Letter.
 
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.
 
Should you have any questions or concerns, please contact me at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov.
 
 
Sincerely,
/S/ 
Ele Ibarra-Pratt
Division Director
Office of Compliance and Enforcement
Center for Tobacco Products
 
 
 
VIA UPS and Electronic Mail
 
cc:
 
Areta Kupchyk
Foley Hoag LLP
1717 K Street NW 
Washington, DC 20006
akupchyk@foleyhoag.com
 
Domains By Proxy, LLC
TINTEDBREW.COM@domainsbyproxy.com 
 
GoDaddy.com
abuse@godaddy.com
 
Shopify Inc.
abuse@shopify.com

 

 
Back to Top